429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

by Antoni Ribas, Olivier Michielin, Reinhard Dummer, Scott Diede, Salvador Martin-Algarra, Sheryl Treichel, Edward Chan
Published 2020-11-01

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

by Matthew C Perez, Jonathan S Zager, Thomas Amatruda, Robert Conry, Charlotte Ariyan, Anupam Desai, John M Kirkwood, Sheryl Treichel, David Cohan, Leon Raskin
Published 2019-06-01